Roche Diabetes Care at IDF 2019

December 2 – 6, 2019, in Busan, South Korea

Order Publications and Solution Brochures

Exhibit Info

Exhibit Info

We look forward to welcoming you to the Roche Diabetes Care exhibition stand!
Find out at the stand how we at Roche Diabetes Care connect the dots, so people with diabetes and their caregivers can put their data to meaningful use.

Conference Location:

Busan Exhibition and Convention Center (BEXCO)

#55 APEC-ro, Haeundae-gu

Busan 48060, Korea


Exhibition Hall 2B

Stand no. G.01

Opening hours:

Tuesday, December 3: 10:00 – 17:00

Wednesday, December 4: 10:00 – 17:00

Thursday, December 5: 10:00 – 17:00

Location map:

Roche Diabetes Care Symposium

Integrated Personalised Diabetes Management: Connecting the dots for true relief

Tuesday, 3 December 2019
Time: 12.00 – 13.00

BEXCO Convention Hall Room #104

Chairs: Julia Mader (Austria), Rolf Hinzmann (Roche Diabetes Care, Germany)


Driving personalised care in diabetes: How modern technology enhances diabetes management

Julia Mader

Medical University of Graz

Graz, Austria

Accuracy of blood glucose monitoring is essential for correct therapy decisions

Rolf Hinzmann

Roche Diabetes Care

Mannheim, Germany

Abstracts & Posters

Empowering patient self-care to improve therapeutic outcomes using the coaching chat function in a mobile diabetes application

Empowering patient self-care to improve therapeutic outcomes using the coaching chat function in a mobile diabetes application

  • OP-0189, Oral Poster Theatre 7, December 4, 12:00 - 13:00 h
  • Author: Chwiecko J. et al.

Receive Roche Diabetes Care solutions brochures and publications links via email!

Order now


Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injec-tion (MDI) Therapy Patients With Suboptimal Glycemic Control: First results from the ABA-CUS trial
(Ziegler et al. Diabetes Care. 2013 Nov;36(11):3613-9.)
Use of an Automated Bolus Calculator in MDI-Treated Type 1 Diabetes - The BolusCal Study, a randomized controlled pilot study
(Schmidt et al. Diabetes Care. 2012 May;35(5):984-90.)
System Accuracy Evaluation of 43 Blood Glucose Monitoring Systems for Self-Monitoring of Blood Glucose According to DIN EN ISO 15197
(Freckmann et al. J Diabetes Sci Technol. 2012 Sep 1;6(5):1060-75.)
Use of a Novel, Remotely Connected Diabetes Management System Is Associated with Increased Treatment Satisfaction, Reduced Diabetes Distress, and Improved Glycemic Control in Individuals with Insulin-Treated Diabetes: First Results from the Personal Diabe-tes Management Study
(Mora et al. Diabetes Technol Ther. 2017 Dec 1; 19(12): 715–22.)
Utilizing eHealth and telemedicine technologies to enhance access and quality
(Barnard et al. Diabetes Technol Ther. 2019 Jun;21(S2):S241-S247.)
A digital-first model of diabetes care
(Cafazzo et al. Diabetes Technol Ther. 2019 Jun;21(S2):S252-S258.)
Real-world assessments of mySugr mobile health app
(Debong et al. Diabetes Technol Ther. 2019 Jun;21(S2):S235-S240.)
Use of artificial intelligence to improve diabetes outcomes in patients using multiple daily injections therapy
(Forlenza et al. Diabetes Technol Ther. 2019 Jun;21(S2):S24-S28.)
The emerging role of telemedicine and mobile health technologies in improving diabetes care
(Garg et al. Diabetes Technol Ther. 2019 Jun;21(S2):S21-S23.)
Current status and future directions for electronic point-of-care clinical decision support
(O’Connor et al. Diabetes Technol Ther. 2019 Jun;21(S2):S226-S234.)
Use of telemedicine technologies in diabetes prevention and control in resource-constrained settings - lessons learned from emerging economies
(Pradeepa et al. Diabetes Technol Ther. 2019 Jun;21(S2):S29-S216.)
Virtual coaching to enhance diabetes care
(Ramchandani et al. Diabetes Technol Ther. 2019 Jun;21(S2):S248-S251.)
Evaluation of a new digital automated glycemic pattern detection tool
(Comellas et al. Diabetes Technol Ther. 2017 Nov 1; 19(11): 633–40.)
Use of Diabetes Data Management Software Reports by Health Care Providers, Patients With Diabetes, and Caregivers Improves Accuracy and Efficiency of Data Analysis and Interpretation Compared With Traditional Logbook Data: First Results of the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES)
(Hinnen et al. J Diabetes Sci Technol. 2015 Mar;9(2):293-301.)
What Do We Need beyond Hemoglobin A1c to Get the Complete Picture of glycemia in people with diabetes?
(Hinzmann et al. Int J Med Sci. 2012;9(8):665-81)
Boluses in insulin therapy
(Ziegler et al. J Diabetes Sci Technol 2017; 11(1):165-71.)
Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study
(Steineck et al. BMJ 2015; 350: h3234.)
Open Source Closed-Loop Insulin Delivery Systems: A Clash of Cultures or Merging of Diverse Approaches?
(Barnard et al. J Diabetes Sci Technol. 2018 Nov;12(6):1223-1226)
Patch Pumps: Are They All the Same?
(Heinemann et al. J Diabetes Sci Technol. 2019 Jan;13(1):34-40.)
Establishing methods to determine clinically relevant bolus and basal rate delivery accuracy of insulin pumps
(Kamecke et al. J Diabetes Sci Technol. 2019 Jan;13(1):60-67.)
Occlusion detection time in insulin pumps at two different basal rates
(Freckmann et al. J Diabetes Sci Technol 2018 ;12(3):608–613)
Continuous subcutaneous insulin infusion: Special needs for children
(Adolfsson et al. Pediatr Diabetes. 2017 Jun;18(4):255-261)
Using insulin pump with a remote-control system in young patients with diabetes improves glycemic control and enhances patient satisfaction
(Deeb et al. Clin Diabetes Endocrinol. 2019 Jun 6;5:7.)
Accuracy of bolus and basal rate delivery of different insulin pump systems
(Freckmann et al. Diabetes Technol Ther. 2019 Apr;21(4):201-208.)
Comparative handling analysis of different insulin pump systems
(Waldenmaier et al. J Diabetes Sci Technol. 2018 Mar; 12(2): 401–406.)
Concept and implementation of a novel patch pump for insulin delivery
(Ulbrich et al. J Diabetes Sci Technol. 2019 Aug [epub])
A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glu-cose Sensor: PRECISE II
(Christiansen et al. Diabetes Technol Ther. 2018 Mar;20(3):197-206.)
Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial
(Kropff et al. Diabetes Care. 2017 Jan;40(1):63-68.)
Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice
(Johnson et al. J Diabetes Sci Technol. 2019 Jun;21(S2):S217-S225.)
Benefits and limitations of MARD as a performance parameter for continuous glucose monitoring in the interstitial space
(Heinemann et al. J Diabetes Sci Technol. 2019 Jun [epub])
Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program
(Kulzer et al. Diab Res Clin Pract. 2018 Oct;144:200-212.)
Integrated Personalized Diabetes Management (PDM): Design of the ProValue Stud-ies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabe-tes.
(Kulzer et al. J Diabetes Sci Technol. 2016 May 3;10(3):772-81.)
PDM-ProValue meets cardiovascular outcome trials in diabetes
(Fritzen et al. Cardiovasc Diabetol. 2019 Jan 28;18(1):10.)
Modeling of Diabetes and Its Clinical Impact
(Fritzen et al. J Diabetes Sci Technol. 2018 Sep;12(5):976-984.)
Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data
(Ravizza et al. Nat Med. 2019 Jan;25(1):57-59.)
A New Optimized Percutaneous Access System for CIPII
(Garcia-Verdugo et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous in-sulin delivery in model predictive control-based fully-automated artificial pancreas in pa-tients with type 1 diabetes: a pilot study.
(Dassau et al. Diabetes Obes Metab. 2017 Dec;19(12):1698-1705.)
Continuous intraperitoneal insulin infusion: an alternative route for insulin delivery in type 1 diabetes.
(Pasquini et al. Acta Diabetol. 2019 Aug. [epub])
New design of a percutaneous port system for continuous intraperitoneal insulin infusion
(Rieger et al. J Diabetes Sci Technol. 2019 Jun [epub])
Twelve-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin a1c and hypoglycemia.
(Dassau et al. Diabetes Care. 2017 Dec;40(12):1719-1726.)
Closed-loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study.
(Breton et al. Diabetes Care. 2017 Dec;40(12):1644-1650.)
Overnight closed-loop control improves glycemic control in a multicenter study of adults with type 1 diabetes
(Brown et al. Clin Endocrinol Metab. 2017 Oct 1;102(10):3674-3682.)
Closed-loop control without meal announcement in type 1 diabetes.
(Cameron et al. Diabetes Technol Ther. 2017 Sep;19(9):527-532.)
Artificial pancreas: clinical study in latin america without premeal insulin boluses.
(Sanchez-Pena et al. J Diabetes Sci Technol. 2018 Sep;12(5):914-925.)
Day-and-night closed-loop control using the unified safety system in adolescents with type 1 diabetes at camp.
(Ly et al. Diabetes Care. 2016 Aug;39(8):e106-7.)
Outpatient closed-loop control with unannounced moderate exercise in adolescents using zone model predictive control
(Huyett et al. Diabetes Technol Ther. 2017 Jun 1; 19(6): 331–339.)

Brochures - Our Solutions:

Accu-Chek® Solo

  • First detachable and tube-free insulin pump
  • Unique quick bolus buttons on pump
  • Diabetes Manager with open bolus advice to combine therapy with continuous glucose monitoring solutions


  • Quick, automated, easy-to-understand logging of BG levels, via Bluetooth®
  • Automatic data integration of leading BG meters (e.g. Accu-Chek Guide), CGM devices (e.g. Eversense), and soon smart pens
  • Bolus advice
  • Easy-to-read reports
  • Personal diabetes coach


  • Up to 6 months wearing time
  • Removable smart transmitter with on-body vibe alerts
  • Predictive alerts before reaching low or high glucose levels
  • Simple, 5-minute in-office insertion
  • Wireless data connection to mySugr

RocheDiabetes Care Platform

  • Provides quick insights to identify patterns and trends to support clinical decision making
  • Enables improved collaboration with patients to help them learning and staying motivated
  • Open connectivity to 130+ devices to increase patient insights and simplify workflow

Accu-Chek® SugarView

  • All you need is a smartphone, an Accu-Chek Active blood glucose test strip, a lancet, and the app to see your blood glucose test range and know what to do next.
  • Feel motivated and assured about your type 2 diabetes as you know your next step.
  • Know how you are doing in between your doctor’s appointments in an affordable way.

Accu-Chek® Guide

  • Easy-to-remove test strips with spill-resistant SmartVial
  • Strip port light, wide, easy-edge test strip, and meter strip ejection
  • Wireless transmission of results to mySugr app

Accu-Chek® Smart Pix

  • Open version allows for read-out of devices from Roche and other manufacturers
  • All data seamlessly available in one system
  • Easy and fast conclusions and therapy adaptations possible
  • Easily understandable visualization of different diabetes-relevant data

Accu-Chek® Insight

  • Intuitive & discreet: Diabetes manager with full remote control with bolus advice, and accurate insulin delivery
  • Easy & safe: Pre-filled cartridge, no air bubbles to remove, sensitive occlusion detection

Accu-Chek® Instant

  • Target Range Indicator – For instant clarity on results
  • Easy navigation – Only 1 button needed!
  • Easy-edge dosing – Wide blood application area compared to leading brands
  • Connection to mySugr app – No more manual diaries